Excellent Daxas® Follow-Up Analysis, From An Anonymous Commenter


One of my favorite anonymous commenters offers us a great update — and on a legacy Schering-Plough COPD candidate story that I completely missed. Of course, Pharmalot had it and I missed it there too. In any event, here it is:

. . . .I missed it too and was made aware of it today based on Pharmalot’s news regarding the recent Daxas® lack of approval in the UK.

Not a big player for Merck but I also noted that Merck has also taken their CXCR2 antagonist off their clinical pipeline chart (legacy S/P compound).

The only COPD drug left is the inhaled steroid/LABA (Dulera, Zenhale and Foradil). [Which is] just a retooling of the asthma medicine.

Interesting — I wonder if they’re giving up on COPD?

January 25, 2012 11:06 AM. . . .

While I doubt that Merck is giving up on COPD meds altogether, I do think this is quite a come-down from the COPD program’s status at legacy Schering-Plough, as most recently outlined here in April of 2010. That former Merck Daxas® distribution partner, Nycomed, is also where an ex-Schering-Plough GC has landed, as of November 2010 (see related graphic, at right — I think Nycomed still handles Alvesco® — anyone know?).

Again — thanks to our erstwhile readership, this place is always made a better (if opinionated) resource.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s